10 analysts have expressed a variety of opinions on Marinus Pharma (NASDAQ:MRNS) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.8, a high estimate of $28.00, and a low estimate of $2.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 20.0%.

Breaking Down Analyst...